title: Suppression of lung and liver carcinogenesis in mice by oral administration of myo-inositol.
abstract: It has been reported that myo-inositol can inhibit carcinogenesis in various organs, such as the mammary gland, colon and lung. In the present study, at first, inhibitory effects of myo-inositol on lung carcinogenesis were confirmed. Then, the influence of myo-inositol on liver carcinogenesis in mice was investigated. In C3H/He male mice, the rate of spontaneous liver carcinogenesis is known to be high. Using this experimental model, the effects of oral administration of myo-inositol (added into the drinking water at the concentration of 1%) were assessed. Significant suppression of liver carcinogenesis was observed in mice treated with myo-inositol for 40 weeks. In the control group without myo-inositol administration, 88% of the animals developed liver tumors, whereas in the myo-inositol-supplemented group, the incidence of liver tumors was 38% (p < 0.05). The average number of liver tumors per mouse was also decreased significantly by myo-inositol treatment; from 7.8 in the control group to 0.8 in the myo-inositol-supplemented group (p < 0.01). Thus, myo-inositol may be useful for cancer chemoprevention in the liver, as well as the lung.
authors.affiliation: Department of Biochemistry, Kyoto Prefectural University of Medicine, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Nishino
authors.forename: M
authors.initials: M
authors.lastname: Murakoshi
authors.forename: M
authors.initials: M
authors.lastname: Masuda
authors.forename: H
authors.initials: H
authors.lastname: Tokuda
authors.forename: Y
authors.initials: Y
authors.lastname: Satomi
authors.forename: M
authors.initials: M
authors.lastname: Onozuka
authors.forename: S
authors.initials: S
authors.lastname: Yamaguchi
authors.forename: P
authors.initials: P
authors.lastname: Bu
authors.forename: A
authors.initials: A
authors.lastname: Tsuruta
authors.forename: K
authors.initials: K
authors.lastname: Nosaka
authors.forename: M
authors.initials: M
authors.lastname: Baba
authors.forename: N
authors.initials: N
authors.lastname: Takasuka
mesh_terms: D000284:Administration, Oral; D000818:Animals; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D007294:Inositol / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000517:prevention & control*; D008175:Lung Neoplasms / Q000517:prevention & control*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H
chemical_list: D016588:Anticarcinogenic Agents; D007294:Inositol